Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effects of olanzapine and aripiprazole on lipolysis in healthy human subcutaneous adipocytes during short incubations

  • Sarsenbayeva, Assel
  • Marques, Cátia
  • Boersma, Gretha
  • Pereira, Maria João
  • Eriksson, Jan W.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Second-generation Antipsychotics (SGAs) have become the treatment of choice over the typical antipsychotics as they provide excellent efficacy and fewer extrapyramidal symptoms. However, the compliance of the patients to SGAs is negatively affected by their ability to induce or aggravate metabolic syndrome, namely, weight gain, insulin resistance, and Type 2 Diabetes. The exact underlying mechanism of metabolic effects of SGAs is not fully elucidated and it is assumed to be at least partially due to their effect on central nervous system. However, whether SGAs have a direct effect on insulin action in the tissues is still to be elucidated. The effect of SGAs on body metabolism varies and we have chosen two drugs, Olanzapine and Aripiprazole, which are associated with high and low risk of metabolic side-effects, respectively. Our research is focused on studying the effect of both SGAs on insulin resistance in human adipose tissue. Aside from lipid storage function, adipose tissue has been recognised, as an endocrine organ, producing hormones, such as adiponectin and leptin, indispensable for energy homeostasis. The set of experiments performed as a part of this study includes measuring the effect of Olanzapine and Aripiprazole on the lipolysis in human isolated adipocytes., [Methods]: Biopsies of subcutaneous adipose tissue (SAT) were collected from 6 patients (3 men, 3 women; age: 20-76 years; BMI: 20.9-34.5 kg/m2). Subjects were free of antidepressants or antipsychotics treatment. At the moment, only the effect of Olanzapine has been tested and measured, the experiments with Aripiprazole are in progress. A 6% adipocyte suspension was incubated with olanzapine (0.004, 0.04, 0.1, 0.2, 2 and 20 μM) or aripiprazole (0.02, 0.2, 0.5, 1, 10 and 100 μM). This was followed by 10 minutes incubation with 4 concentrations of insulin (0.1 μU; 1.0 μU; 10 μU; 100 μU) and then incubated with 0.5 μM ß-adrenergic receptor agonist, Isopretenerol, for 1h 50 min. ß-adrenergic stimulation activates hormone-sensitive lipase (HSL) enzyme via cAMP-dependent pathway. HSL, in turn, hydrolyses tritriacylglycerol (TAG), diacylglycerol (DAG) or monoacylglycerol (MAG) molecules producing free fatty acids and glycerol. The supernatant was then collected and used for glycerol measurement., [Results]: Short incubations of adipocytes with therapeutic concentrations of Olanzapine show no effect in lipolysis. The highest concentration of the drug hints at a reduced rate of lipolysis in adipocytes by more than 50% for each insulin concentration (p<0.0001) and in control conditions (p<0.01)., [Conclusions]: Therefore, it seems that short-term incubation of adipocytes with 20 μM Olanzapine reduces the rate of lipolysis, while the therapeutic concentrations do not seem to alter lipolysis in adipocytes., This work is being supported by Marie Skłodowska Curie Actions (H2020-MSCA-ITN-2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effects of olanzapine and aripiprazole on glucose uptake in healthy human subcutaneous adipocytes during short incubations

  • Marques, Cátia
  • Sarsenbayeva, Assel
  • Boersma, Gretha
  • Valverde, Ángela M.
  • Carvalho, Eugenia
  • Pereira, Maria João
  • Eriksson, Jan W.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Second-generation Antipsychotics (SGAs) are preferable pharmacological treatment for patients with Schizophrenia, mainly due to their efficacy and reduced risk of extrapyramidal effects when compared with first generation antipsychotics. However, there are metabolic side effects associated with the administration of SGAs, namely weight gain, dyslipidaemia and impaired glucose metabolism. Literature reports that even in the absence of antipsychotic treatment patients with Schizophrenia have a propensity to develop metabolic changes that can lead to cardiovascular diseases, insulin resistance, obesity and Type 2 Diabetes. Olanzapine and aripiprazole belong to SGAs and have been reported as drugs with the highest and the lowest risk of inducing metabolic changes, respectively. However, the pharmacological mechanisms underlying their metabolic side effects remain unclear and they will be the main focus of our study. Adipose tissue is not only specialized in storing lipids but it is also an endocrine organ that produces and secretes numerous biological active compounds that regulate metabolic homeostasis. Our aim is to evaluate the effect of olanzapine and aripiprazole in the glucose uptake on human isolated adipocytes., [Methods]: Biopsies of subcutaneous adipose tissue were collected from 16 healthy volunteers (4 men, 12 women; age: 20-76 years; BMI: 20.9-34.5 kg/m2). Subjects taking antidepressants or antipsychotics were not included. The effect of short-term incubation (30 min) with different concentrations of olanzapine (0.004, 0.04, 0.1, 0.2, 2 and 20 μM) or aripiprazole (0.02, 0.2, 0.5, 1, 10 and 100 μM) on basal and insulin-stimulated (25 and 1000 μU/ml) D-[U-14C]-glucose uptake of isolated adipocytes was measured and compared with control., [Results]: Short incubation of adipocytes with olanzapine or aripiprazole showed no effect on basal or insulin-stimulated glucose uptake, with the exception of supra-physiological concentrations of aripiprazole (10 and 100 μM) where we see a systematic decrease of basal and insulin-stimulated glucose uptake; 10 μM by ͌20-25% (p<0.05) and 100 μM by ͌60-70% (p<0.01)., [Conclusions]: Short-term treatment of isolated adipocytes with therapeutic doses of olanzapine or aripiprazole did not affect glucose uptake, suggesting no acute alteration in insulin activity. These data suggest that the plasma glucose increase seen in patients taking Olanzapine cannot be justified by acute alteration in insulin-signalling in adipocytes. Incubation with aripiprazole at 10 and 100 μM decreased the adipocyte glucose uptake but this might be justified by cell death, which will be explored in future experiments., This work is being supported by Marie Skłodowska Curie Actions (H2020-MSCA-ITN-2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Modulation of SIRT1 by IL-1β/NFκB signaling during Acetaminophen-induced hepatotoxicity

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz, Laura
  • González-Rodríguez, Águeda
  • Sánchez-Ramos, Cristina
  • Muntané, Jordi
  • Alemany, Susana
  • Monsalve, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The liver is the main organ in charge of drug catabolism and also the major site susceptible to drug injury. Sirtuin 1 (SIRT1), a NAD+-dependent histone deacetylase, is a key player in liver physiology and a therapeutic target against hepatic inflammation. In this study, we evaluated the role of SIRT1 in the pro-inflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Material and Methods]: SIRT1 expression was analyzed in APAP-induced liver failure in humans and mice. Hepatotoxicity was assessed in wild-type and transgenic mice overexpressing SIRT1 (SIRT1 Tg) poisoned with APAP (300 mg/kg). Raw 264.7 and peritoneal macrophages were treated with APAP and conditioned medium (CM) was added to mouse hepatocytes. siRNA was used to reduce inflammatory mediators in hepatocytes., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 upon APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, pro-inflammatory cytokine mRNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin 1β (IL1β), an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant. Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; SAF2014-52009-R (MINECO/FEDER) to S.A; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A. G-R; PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII, Spain) to A. G-R and J.M; Grant 37/371 from Al Jouf University (to M.A.M). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Using omics approaches to develop a biomarker signature for anti-psychotic drug toxicity

  • Bupalan, Sangeetha
  • Samali, Afshin
  • Gorman, Adrienne M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Schizophrenia (SCZ) is a chronic brain disorder with symptoms of hallucinations, delusions, disturbed behavior and emotional and cognitive impairment. These symptoms are managed by administration of antipsychotic drugs (APDs), either as a single APD or a combination of different APDs depending on the individual. It is always recommended to take a maintenance dose of APD even after the reduction of SCZ symptoms which makes it a lifelong treatment. APD treatment is currently known to be the only effective treatment against SCZ. However, they are observed to trigger metabolic dysfunctions such as insulin resistance, obesity, coronary heart diseases and dyslipedemia in SCZ patients at the later stage during APD treatment. The main aim of the project is to identify a biomarker signature that could be detected in blood to diagnose the metabolic dysfunction due to APD administration at an early stage. The talk will provide an insight into omic approaches for biomarker discovery and a worked example of these approaches using relevant existing data sets from public repositories., [Materials and Methods]: The public repository Array Express (AE) (https://www.ebi.ac.uk/arrayexpress/) was used to shortlist the datasets from transcriptomic studies of primary human hepatocytes (PHH) that has been treated with any antipsychotic drug. R studio was used to process the data and shortlist genes that had a minimum fold change of 2. Bioinfominer online tool (https://bioinfominer.com/) was used for Gene ontology enrichment analysis., [Results and conclusion]: We found a microarray dataset of PHH that has been treated with Chlorpromazine (APD) from AE (AE id: E-MTAB-1747). The deregulated gene list from PHH that were treated with CPZ was significantly grouped under inflammatory and immune response from the gene ontology term enrichment analysis. Since the gene products of the inflammatory/immune response are mostly secreted, they are likely to be detected in blood which makes them potential biomarker candidates. However, these candidates were identified from PHH isolated from a single donor, so more work would be required to confirm them as valid biomarkers. Despite that caveat, the gene list can be considered as a useful reference list for future experiments., H2020-MSCA-ETN-2016-72123., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Measurement of polymorphic P-glycoprotein activity in cell cultures: a review

  • Zubiaur, Pablo
  • Saiz-Rodríguez, Miriam
  • Koller, Dora
  • Ovejero-Benito, M. C.
  • Abad-Santos, Francisco
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The P-glycoprotein (P-gp) is an efflux pump widely expressed in the organism that exports xenobiotic compounds out of the tissue where it is expressed. It plays a central role in the Blood-Brain Barrier permeability, being responsible of Central Nervous System side-effects or ineffectiveness of many drugs. Several single-nucleotide polymorphisms (SNPs) in ABCB1 (the gene encoding for P-gp) have been identified. The most relevant ones, C3435T, C2677T/A and C1236T have been associated with variable pharmacokinetic parameters in healthy volunteers that received single oral doses of antidepressants and antipsychotics. There is no consensus regarding the in vivo effect they have. Here, we compile relevant information in order to simplify the understanding of materials, methods and cell lines classically used to assess polymorphic P-gp activity in in vitro cell culture models., [Methods]: A comprehensive research of the studies performed in this regard has been accomplished. More than 389 articles have been reviewed, corresponding to the topics “ABCB1 polymorphisms”, “assessment of P-gp function” and “P-gp expression in cell cultures” published in PubMed Search Engine., [Results]: Twenty-four articles have been summarised and classified. Site-directed mutagenesis has been acknowledged as a convenient approach to obtain cell lines expressing mutant P-gp. Ten different techniques have been identified as key in the assessment of P-gp function: Transfection; Western Blot; Flow Cytometry; Transcriptional Analysis; TEER measurements; Calcein-AM, Rhodamine-123 or Radioactivity based accumulation and transport assays; Transwell® inserts; MTT viability assays., [Conclusion]: Site-directed mutagenesis performed in plasmids that contain wild-type ABCB1, followed by transfection of the plasmid into cells (HeLa, Caco-2 cells) may lead to cell lines expressing P-gp with the SNPs of interest (C3435T, C2677T/A and C1236T). Assessment of P-gp function may be accomplished by Calcein-AM or Rhodamine-123 accumulation assays. The actual effect of these SNPs in P-gp on antidepressants or antipsychotics efflux through membranes could be assessed by Transwell® insert transport assays., P. Zubiaur is co-financed by Consejería de Educación, Juventud y Deporte from Comunidad de Madrid and Fondo Social Europeo. D. Koller is co-financed by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

PTP1B deficiency protects mice against metabolic dysfunction in glucose homeostasis upon Olanzapine intraperitoneal treatment

  • Ferreira, Vítor
  • Rada, Patricia
  • Grajales, Diana
  • García Martínez, Irma
  • Valverde, Ángela M.
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Schizophrenia is a chronic mental disorder that affects approximately 50 million people worldwide. Also, it is associated with psychotic experiences that not allow patients to have a normal life. Fortunately, treatments used can suppress the symptomatology and lead to a productive life and integration in the society. According to the current guidelines, the first line in schizophrenia’s therapy are the second generation antipsychotic drugs (SGA). Besides being D2 receptors antagonists/partial agonists, the SGAs have the ability to interact also with serotonergic, histaminergic and other receptors; minimizing the symptomatology and not resulting in neurological side effects (contrarily to first generation antipsychotic drugs). Nevertheless, recent clinical observations show a variety of metabolic dysfunctions in patients under SGAs treatment, such as abnormal gain weight, hyperglycemia and dyslipidemia. However, the molecular mechanisms behind these alterations are still very poorly understood. Having this in consideration, the objective of this work was to study the effect of Olanzapine administration in wild-type (WT) and PTP1B-deficient (KO) mice on glucose homeostasis and the mechanisms involved. Of interest, PTP1B is the main tyrosine phosphatase of the insulin receptor, and PTP1B KO mice are protected against insulin resistance and development of type 2 diabetes mellitus. After administration of 10 mg/kg/day of Olanzapine for 8 weeks to WT and PTP1B-KO mice, the glucose homeostasis tests suggest that Olanzapine induced insulin resistance only in WT mice. Also, primary hepatocytes from WT mice treated with Olanzapine showed lower glucose uptake than those from non-treated WT mice. In contrast, Olanzapine treatment of PTP1B KO mice significantly increased hepatocyte glucose uptake, suggesting that Olanzapine-induced insulin resistance is at least in part dependent on PTP1B. These results support the relevance of PTP1B in Olanzapine-induced insulin resistance in hepatocytes., European Union's EU Framework Programme for Research and Innovation Horizon 2020. ITN-TREATMENT under Grant Agreement No GA 721236., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

PTP1B deficiency protects mice against metabolic dysfunction in glucose homeostasisupon Olanzapine intraperitoneal treatment

  • Silva Ferreira, Vítor Manuel Da
  • Rada, Patricia
  • Grajales, Diana
  • García Martínez, Irma
  • Valverde, Ángela M.
Comunicación presentada en el 6th Symposium on Biomedical Research Advances and Perspectives in Molecular Endocrinology, celebrado en Madrid (España), el 31 de mayo de 2019., Schizophrenia is a chronic mental disorder that affects approximately 50 million people worldwide. Also, it is associated with psychotic experiences that not allow patients to have a normal life. Fortunately, treatments used can suppress the symptomatology and lead to a productive life and integration in the society. According to the current guidelines, the first line in schizophrenia’s therapy are the second generation antipsychotic drugs (SGA). Besides being D2 receptors antagonists/ partial agonists, the SGAs have the ability to interact also with serotonergic, histaminergic and other receptors; minimizing the symptomatology and not resulting in neurological side effects (contrarily to first generation antipsychotic drugs). Nevertheless, recent clinical observations show a variety of metabolic dysfunctions in patients under SGAs treatment, such as abnormal gain weight, hyperglycemia and dyslipidemia. However, the molecular mechanisms behind these alterations are still very poorly understood. Having this in consideration, the objective of this work was to study the effect of Olanzapine administration in wild-type (WT) and PTP1B-deficient (KO) mice on glucose homeostasis and the mechanisms involved. Of interest, PTP1B is the main tyrosine phosphatase of the insulin receptor, and PTP1B KO mice are protected against insulin resistance and development of type 2 diabetes mellitus. After administration of 10 mg/kg/day of Olanzapine for 8 weeks to WT and PTP1B-KO mice, the glucose homeostasis tests suggest that Olanzapine induced insulin resistance only in WT mice. Also, primary hepatocytes from WT mice treated with Olanzapine showed lower glucose uptake than those from non-treated WT mice. In contrast, Olanzapine treatment of PTP1B KO mice significantly increased hepatocyte glucose uptake, suggesting that Olanzapine-induced insulin resistance is at least in part dependent on PTP1B. These results support the relevance of PTP1B in Olanzapine-induced insulin resistance in hepatocytes., European Union's EU Framework Programme for Research and Innovation Horizon 202. ITN-TREATMENT under Grant Agreement No GA 721236
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Modulation of SIRT1 by IL1b/NFkB signaling during acetaminophen-induced hepatotoxicity

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz-Cañas, Laura
  • Sánchez-Ramos, Cristina
  • Alemany, Susana
  • Monsalve, María
  • Valverde, Ángela M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The liver is the main organ in charge of drug catabolism and also the major site susceptible to drug injury. Sirtuin 1 (SIRT1), a NAD+-dependent histone deacetylase, is a key player in liver physiology and a therapeutic target against hepatic inflammation. In this study, we evaluated the role of SIRT1 in the pro-inflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Material and Methods]: SIRT1 expression was analyzed in APAP-induced liver failure in humans and mice. Hepatotoxicity was assessed in wild-type and transgenic mice overexpressing SIRT1 (SIRT1 Tg) poisoned with APAP (300 mg/kg). Raw 264.7 and peritoneal macrophages were treated with APAP and conditioned medium (CM) was added to mouse hepatocytes. siRNA was used to reduce inflammatory mediators in hepatocytes., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 upon APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, pro-inflammatory cytokine mRNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin 1β (IL1β), an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant. Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; SAF2014-52009-R (MINECO/FEDER) to S.A; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A. G-R; PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII, Spain) to A. G-R and J.M; Grant 37/371 from Al Jouf University (to M.A.M). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission).